Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nautilus Neurosciences and Mission Pharmacal have signed an exclusive co-promotion agreement for Cambia (diclofenac potassium for oral solution) to obstetrician's, gynecologists and other women's health medical professionals.
Subscribe to our email newsletter
Cambia, a new water-soluble, buffered diclofenac potassium powder, is a prescription non-steroidal anti-inflammatory drug (NSAID) available for the acute treatment of migraine.
The companies claimed that Cambia which is designed for fast, effective relief from the symptoms of migraine.
The companies further said that Cambia is engineered using Dynamic Buffering Technology (DBT), a patented absorption-enhancing technology developed by APR Applied Pharma Research.
Cambia has received US approval for the acute treatment of migraine with or without aura and was launched in the US in June 2010.